Atara Biotherapeutics (STU:AT20) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


STU:AT20 Atara Biotherapeutics Inc STU:AT20
31 GF Score
Price €8.80
GF Value €1.30
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Atara Biotherapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:AT20 vs RNTX, IBIO, OSTX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Margin of Safety % (DCF Earnings Based) falls into.


STU:AT20
31GF Score
Atara Biotherapeutics Inc STU:AT20
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Atara Biotherapeutics (STU:AT20) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of €8.80 is trading 576.7% above its estimated GF Value™ of €1.30.

Key valuation signals for STU:AT20:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.30 vs. price of €8.80 (576.7% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the STU:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges ATRA:USA0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for STU:AT20

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.80
Price
€1.30
GF Value